Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
22 May 2024
Expected end
April 2027
Enrollment
100 participants
Sites
3
Primary outcomes
Nature and frequency of dose limiting toxicities per Common Toxicity Criteria for Adverse Events version 5; Change in systolic and diastolic BP,; Change in Heart Rate; Changes in Temperature measurements.; Change in pulse ox measurements on room air
Sponsor type
Industry
Results posted
No
Last update
2 April 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.